Central Nervous System

SS 13 - CNS 2 - Gliomas

95 - Analysis of RTOG-RPA Scores in the Phase 3 EF-14 Trial of Tumor Treating Fields With Temozolomide (TTFields/TMZ) Versus TMZ Alone in Newly Diagnosed Glioblastoma.

Monday, October 22
11:15 AM - 11:25 AM
Location: Room 004

Analysis of RTOG-RPA Scores in the Phase 3 EF-14 Trial of Tumor Treating Fields With Temozolomide (TTFields/TMZ) Versus TMZ Alone in Newly Diagnosed Glioblastoma.
K. Choe; Radiation Oncology Associates, Falls Church, VA

Purpose/Objective(s): In the simplified recursive partitioning analysis (RPA) model for survival of glioblastoma patients by the Radiation Therapy Oncology Group (RTOG) patients are divided into three prognostic groups based on four variables: age, performance status, extent of resection, and neurologic function. The EF-14 phase 3 trial of TTFields/TMZ compared to TMZ alone showed that adding TTFields to TMZ increased overall survival (OS) of newly diagnosed glioblastoma patients. RTOG-RPA scores were analyzed in the phase 3 EF-14.

Materials/Methods: We applied the RTOG-RPA classes on the EF-14 population. OS of both arms of the EF-14 trial were compared to that of the original validation cohort used to develop the simplified RTOG-RPA model.

Results: OS for the TMZ alone arm were similar to the RTOG validation dataset in all three RPA classes. OS in the TTFields/TMZ arm were improved compared to both the TMZ alone arm and the RTOG validation cohort in all three RPA classes. The 3-year OS for the RTOG, EF-14 TMZ alone and EF-14 TMZ/TTFields cohorts were: RPA class III – 20%, 25% and 39%; RPA class IV: 7%, 15% and 23%; RPA class V+VI: 1%, 9% and 20%, respectively. Median OS was significantly longer in the TTFields/TMZ arm than the TMZ alone arm for RPA class III (26.2 versus 20.0 months, p=0.030) and RPA class 1V (20.0 versus 15.6 months, p=0.0005) but not for RPA Class V+VI (10.9 versus 12.6 months, p=0.213).

Conclusion: This analysis validates the consistency of the EF-14 trial with historical control data. When analyzed using the simplified RTOG-RPA model, TTFields/TMZ compared to TMZ alone shows improved OS out to 5 years, regardless of patients’ prognostic factors.

Author Disclosure: K. Choe: Honoraria; Novocure.

Kevin Choe, MD, PhD

Disclosure:
Compensation
Novocure: Honoraria

Presentation(s):

Send Email for Kevin Choe


Assets

95 - Analysis of RTOG-RPA Scores in the Phase 3 EF-14 Trial of Tumor Treating Fields With Temozolomide (TTFields/TMZ) Versus TMZ Alone in Newly Diagnosed Glioblastoma.



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Analysis of RTOG-RPA Scores in the Phase 3 EF-14 Trial of Tumor Treating Fields With Temozolomide (TTFields/TMZ) Versus TMZ Alone in Newly Diagnosed Glioblastoma.